

SCEMBLIX - Initiation and dosing - HCP

[Prescribing information](#)

Image



Image



 **SCSEMBLIX**[®] ▼
(asciminib) 20 mg, 40 mg tablets

SCSEMBLIX[®] ▼ (asciminib) is indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukaemia (Ph + CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors, and without a known T315I mutation.¹

Initiation and dosing

SCSEMBLIX[®] ▼ (asciminib) has a once- or twice-daily oral dosing¹

Recommended dosage in adult patients with Ph+ CML-CP, previously treated with ≥ 2 TKIs and without a known T315I mutation.¹

- [Recommended dosage¹](#)

- [Dose modification schedule¹](#)

Image



80 mg OD

SCEMBLIX should be taken at approximately the same time every day.

If a SCEMBLIX dose is missed by more than 12 hours, advise the patient to skip the dose and take the next dose as scheduled.¹

Image

40 mg BD

AM + PM

SCEMBLIX should be taken twice daily at approximately 12-hour intervals.²

If a SCEMBLIX dose is missed by more than 6 hours, advise the patient to skip the dose and take the next dose as scheduled.¹

Image




Patients should avoid food for at least 2 hours before and 1 hour after taking SCEMBLIX.¹

Image



SCEMBLIX tablets should be swallowed whole with a glass of water – patients should not break, crush or chew them.¹

Image



Not actual sizes.

SCEMBLIX is available as film-coated tablets.

- [Recommended dosage¹](#)

- [Dose modification schedule¹](#)

Patients changing from 40 mg twice daily to 80 mg once daily should start taking SCEMBLIX once daily approximately 12 hours after the last twice-daily dose, and then continue at 80 mg once daily.

Patients changing from 80 mg once daily to 40 mg twice daily should start taking SCEMBLIX twice daily approximately 24 hours after the last once-daily dose and then continue at 40 mg twice daily at approximately 12-hour intervals.

For the management of adverse reactions, the SCEMBLIX dose can be reduced based on individual tolerability.

Image

Starting SCEMBLIX dose	Modification guidelines
80 mg OD	<p>To reduce, decrease dose to 40 mg OD</p> <p>To resume, increase dose to 80 mg OD</p>
40 mg BD	<p>To reduce, decrease dose to 20 mg BD</p> <p>To resume, increase dose to 40 mg BD</p>

SCEMBLIX should be permanently discontinued in patients unable to tolerate a total daily dose of 40 mg.¹

Since there are no data available in patients with moderate or severe hepatic impairment, caution should be exercised in these patients.¹

Withholding SCEMBLIX followed by potential dose reductions and/or permanent discontinuations may be required in case of thrombocytopenia and/or neutropenia, asymptomatic amylase and/or lipase elevation and non-haematological grade ≥ 3 adverse reactions.

Asciminib dose modification schedule for the management of adverse reactions

Adverse reaction

Dosage modification

Thrombocytopenia and/or neutropenia

ANC $< 1.0 \times 10^9/l$ and/or PLT $< 50 \times 10^9/l$

Withhold asciminib until resolved to ANC $\geq 1 \times 10^9/l$ and/or PLT $\geq 50 \times 10^9/l$.

If resolved:

- Within 2 weeks: resume at starting dose.
- After more than 2 weeks: resume at reduced dose. For recurrent severe thrombocytopenia and/or neutropenia, withhold asciminib until resolved to ANC $\geq 1 \times 10^9/l$ and PLT $\geq 50 \times 10^9/l$, then resume at reduced dose.

Asymptomatic amylase and/or lipase elevation

Elevation >2.0 x ULN

Withhold asciminib until resolved to <1.5 x ULN.

- If resolved: resume at reduced dose. If events reoccur at reduced dose, permanently discontinue.
- If not resolved: permanently discontinue. Perform diagnostic tests to exclude pancreatitis.

Non-haematological adverse reactions

Grade 3 or higher adverse reactions¹

Withhold asciminib until resolved to grade 1 or lower.

- If resolved: resume at a reduced dose.
- If not resolved: permanently discontinue.

ANC: absolute neutrophil count; PLT: platelets; ULN: upper limit of normal.

¹Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v 4.03.

Please refer to the Summary of Product Characteristics for the detailed guidance on managing each of these adverse events and on dose modification of SCEMBLIX.¹

Please refer to the Summary of Product Characteristics for further information on changing between dosing schedules for the recommended dose of SCEMBLIX.¹

SCEMBLIX, an opportunity to manage \geq 3rd-line patients with a flexible dosing schedule¹

Regular monitoring is important to assess treatment benefits and inform a decision to switch^{2,3}

[Discover more](#)

BD, twice daily; CML, chronic myeloid leukaemia; OD, once daily; Ph+ CML-CP, Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase; TKI, tyrosine kinase inhibitor.

For further information, please refer to the [Summary of Product Characteristics](#).

References

1. SCEMBLIX (asciminib) Summary of Product Characteristics.
2. Smith G, et al. *Br J Haematol* 2020;191(2):171-193.

3. Hochhaus A, et al. *Leukemia* 2020;34:966–984.

UK | November 2024 | FA-11311714

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email medinfo.uk@novartis.com or call 01276 698370.

Source URL:

<https://www.pro.novartis.com/uk-en/medicines/haematology/scemblix/initiation-and-dosing>